These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 7484368

  • 1. Metabolism of cyclophosphamide by aldehyde dehydrogenases.
    Agarwal DP, von Eitzen U, Meier-Tackmann D, Goedde HW.
    Adv Exp Med Biol; 1995; 372():115-22. PubMed ID: 7484368
    [No Abstract] [Full Text] [Related]

  • 2. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase.
    Rekha GK, Sreerama L, Sladek NE.
    Biochem Pharmacol; 1994 Nov 16; 48(10):1943-52. PubMed ID: 7986206
    [Abstract] [Full Text] [Related]

  • 3. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.
    Sládek NE.
    Curr Pharm Des; 1999 Aug 16; 5(8):607-25. PubMed ID: 10469894
    [Abstract] [Full Text] [Related]

  • 4. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines.
    Kohn FR, Landkamer GJ, Manthey CL, Ramsay NK, Sladek NE.
    Cancer Res; 1987 Jun 15; 47(12):3180-5. PubMed ID: 3034402
    [Abstract] [Full Text] [Related]

  • 5. Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes.
    von Eitzen U, Meier-Tackmann D, Agarwal DP, Goedde HW.
    Cancer Lett; 1994 Jan 15; 76(1):45-9. PubMed ID: 8124665
    [Abstract] [Full Text] [Related]

  • 6. Metabolism of oxazaphosphorines.
    Sladek NE.
    Pharmacol Ther; 1988 Jan 15; 37(3):301-55. PubMed ID: 3290910
    [No Abstract] [Full Text] [Related]

  • 7. Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification.
    Manthey CL, Landkamer GJ, Sladek NE.
    Cancer Res; 1990 Aug 15; 50(16):4991-5002. PubMed ID: 2379164
    [Abstract] [Full Text] [Related]

  • 8. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3.
    Giorgianni F, Bridson PK, Sorrentino BP, Pohl J, Blakley RL.
    Biochem Pharmacol; 2000 Aug 01; 60(3):325-38. PubMed ID: 10856427
    [Abstract] [Full Text] [Related]

  • 9. Role of metabolites of cyclophosphamide in cardiotoxicity.
    Kurauchi K, Nishikawa T, Miyahara E, Okamoto Y, Kawano Y.
    BMC Res Notes; 2017 Aug 14; 10(1):406. PubMed ID: 28807058
    [Abstract] [Full Text] [Related]

  • 10. Effect of stereochemistry on the oxidative metabolism of the cyclophosphamide metabolite aldophosphamide.
    Habib AD, Boal JH, Hilton J, Nguyen T, Chang YH, Ludeman SM.
    Biochem Pharmacol; 1995 Jul 31; 50(3):429-33. PubMed ID: 7646546
    [Abstract] [Full Text] [Related]

  • 11. Xenobiotic oxidation catalyzed by aldehyde dehydrogenases.
    Sladek NE, Manthey CL, Maki PA, Zhang Z, Landkamer GJ.
    Drug Metab Rev; 1989 Jul 31; 20(2-4):697-720. PubMed ID: 2680404
    [No Abstract] [Full Text] [Related]

  • 12. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia.
    Hilton J.
    Cancer Res; 1984 Nov 31; 44(11):5156-60. PubMed ID: 6488175
    [Abstract] [Full Text] [Related]

  • 13. Inhibition by cyanamide of 4-hydroxycyclophosphamide/aldophosphamide oxidation to carboxyphosphamide.
    Domeyer BE, Sladek NE.
    Biochem Pharmacol; 1981 Aug 01; 30(15):2065-73. PubMed ID: 7295327
    [No Abstract] [Full Text] [Related]

  • 14. Kinetic characterization of the catalysis of "activated" cyclophosphamide (4-hydroxycyclophosphamide/aldophosphamide) oxidation to carboxyphosphamide by mouse hepatic aldehyde dehydrogenases.
    Manthey CL, Sladek NE.
    Biochem Pharmacol; 1988 Jul 15; 37(14):2781-90. PubMed ID: 3395357
    [Abstract] [Full Text] [Related]

  • 15. Constitutive and overexpressed human cytosolic class-3 aldehyde dehydrogenases in normal and neoplastic cells/secretions.
    Sladek NE, Sreerama L, Rekha GK.
    Adv Exp Med Biol; 1995 Jul 15; 372():103-14. PubMed ID: 7484367
    [No Abstract] [Full Text] [Related]

  • 16. Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?
    Ludeman SM, Gamcsik MP.
    Cancer Treat Res; 2002 Jul 15; 112():177-97. PubMed ID: 12481717
    [No Abstract] [Full Text] [Related]

  • 17. The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues.
    Andersson BS, Mroue M, Britten RA, Murray D.
    Cancer Res; 1994 Oct 15; 54(20):5394-400. PubMed ID: 7923171
    [Abstract] [Full Text] [Related]

  • 18. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide.
    Crook TR, Souhami RL, Whyman GD, McLean AE.
    Cancer Res; 1986 Oct 15; 46(10):5035-8. PubMed ID: 3463410
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line.
    Andersson BS, Mroue M, Britten RA, Farquhar D, Murray D.
    Acta Oncol; 1995 Oct 15; 34(2):247-51. PubMed ID: 7718264
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol.
    Rekha GK, Sladek NE.
    Adv Exp Med Biol; 1997 Oct 15; 414():133-46. PubMed ID: 9059615
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.